Latest Licensing News

Osteopore Limited posted a 10% quarter-on-quarter revenue increase to AUD 754K in Q1 CY26, driven by new distribution deals across China, Latin America, and Hong Kong, alongside launching 3D printing services and securing innovative bone graft technologies in Asia Pacific.

Ore Resources (ASX: OR3) has expanded high-grade gold mineralisation at its Forrest prospect through Phase 3 and Phase 4 drilling, while significantly growing its landholdings in the Eastern Goldfields. The company is well funded with A$9.6 million cash, preparing for a busy exploration season with assay results due in May.

Meteoric Resources has reported strong pilot plant performance and advanced feasibility work at its Caldeira rare earths project, alongside a $50 million non-binding financing letter from Export Finance Australia and robust Brazilian government backing.

CurveBeam AI reported stable device orders but faces regulatory delays for FDA and China clearances, while securing a A$4 million investment from WEGO Orthopaedics and advancing clinical collaborations with robotic surgery systems.

Altech Batteries has won conditional approval for a €46.11 million German government grant supporting its CERENERGY® Sodium-Chloride Solid-State battery project, while shifting its Silumina AnodesTM R&D operations to Germany to enhance efficiency and cut costs.

Syntara Limited has raised A$10 million through a two-tranche placement and share purchase plan, backing its Phase 2b myelofibrosis trial and multiple clinical readouts following positive FDA feedback.

eMetals Limited has solidified its foothold in high-grade tungsten with a binding acquisition in Utah, while its Ugandan gold projects reveal promising soil anomalies amid ongoing exploration.

Emyria Limited is extending its Empax mental health clinic network into New South Wales through a new partnership with Matilda Nepean Private Hospital, increasing treatment capacity and national reach ahead of a planned Q3 2026 launch.

Avecho Biotechnology has exceeded its Phase III CBD insomnia trial recruitment target by 16%, setting the stage for a more robust interim analysis scheduled for June 2026. The company’s commercial partnership with Sandoz AG and strengthened patent portfolio underpin its Australian market strategy.

Lotus Resources has completed the first phase of a 10,000m infill drill program at its Letlhakane Uranium Project, revealing significant higher-grade uranium intercepts that underpin a resource upgrade planned for H2 2026.

AdAlta has secured Australian manufacturing for its lead CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients. This move is a key step toward local clinical trials and boosts the therapy’s global commercial appeal.

Alcidion Group delivered positive cashflow and strong new sales in Q3 FY26, with contract expansions in the UK and Australia. The company remains on track for a significant Electronic Patient Record contract signing in May.